Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets

Laurent O. Mosnier; Paula Buijtenhuijs; Pauline F. Marx; Joost C. M. Meijers; Bonno N. Bouma

doi:https://doi.org/10.1182/blood-2002-09-2944

Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets

Laurent O. Mosnier, Paula Buijtenhuijs, Pauline F. Marx, Joost C. M. Meijers, Bonno N. Bouma

Research output: Contribution to journal › Article › Academic › peer-review

108 Citations (Scopus)

Abstract

Thrombin activatable fibrinolysis inhibitor (TAFI) is a carboxypeptidase B-like proenzyme that after activation downregulates fibrinolysis. Platelets are known to contain antifibrinolytic factors that are secreted during platelet activation. Therefore, the presence of TAFI in platelets was analyzed. TAFI was identified in platelets in a concentration of about 50 ng/1 x 10(9) platelets and was secreted on platelet activation. Thrombi n-mediated activation of platelet-derived TAFI resembled that of plasma-derived TAFI with respect to stimulation by thrombomodulin and spontaneous loss of activity at 37degreesC. The different glycosylation of platelet-derived TAFI compared with plasma-derived TAFI suggets that platelet-derived TAFI is synthesized in the megakaryocyte. This suggestion was substantiated by the detection of mRNA in the megakaryocytic cell lines DAMI and CHRF, representing the intermediate and late stages of megalkaryocyte development. These results establish the presence of TAFI in platelets and suggest a role for platelet-derived TAFI in the protection of the clot against fibrinolysis. (Blood. 2003;101:4844-4846)

Original language	English
Pages (from-to)	4844-4846
Journal	Blood
Volume	101
Issue number	12
DOIs	https://doi.org/10.1182/blood-2002-09-2944
Publication status	Published - 2003

Access to Document

https://doi.org/10.1182/blood-2002-09-2944

Cite this

@article{05a9e09ec9dc491b9935b53fc5eda523,

title = "Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets",

abstract = "Thrombin activatable fibrinolysis inhibitor (TAFI) is a carboxypeptidase B-like proenzyme that after activation downregulates fibrinolysis. Platelets are known to contain antifibrinolytic factors that are secreted during platelet activation. Therefore, the presence of TAFI in platelets was analyzed. TAFI was identified in platelets in a concentration of about 50 ng/1 x 10(9) platelets and was secreted on platelet activation. Thrombi n-mediated activation of platelet-derived TAFI resembled that of plasma-derived TAFI with respect to stimulation by thrombomodulin and spontaneous loss of activity at 37degreesC. The different glycosylation of platelet-derived TAFI compared with plasma-derived TAFI suggets that platelet-derived TAFI is synthesized in the megakaryocyte. This suggestion was substantiated by the detection of mRNA in the megakaryocytic cell lines DAMI and CHRF, representing the intermediate and late stages of megalkaryocyte development. These results establish the presence of TAFI in platelets and suggest a role for platelet-derived TAFI in the protection of the clot against fibrinolysis. (Blood. 2003;101:4844-4846)",

author = "Mosnier, {Laurent O.} and Paula Buijtenhuijs and Marx, {Pauline F.} and Meijers, {Joost C. M.} and Bouma, {Bonno N.}",

year = "2003",

doi = "https://doi.org/10.1182/blood-2002-09-2944",

language = "English",

volume = "101",

pages = "4844--4846",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "12",

}

TY - JOUR

T1 - Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets

AU - Mosnier, Laurent O.

AU - Buijtenhuijs, Paula

AU - Marx, Pauline F.

AU - Meijers, Joost C. M.

AU - Bouma, Bonno N.

PY - 2003

Y1 - 2003

N2 - Thrombin activatable fibrinolysis inhibitor (TAFI) is a carboxypeptidase B-like proenzyme that after activation downregulates fibrinolysis. Platelets are known to contain antifibrinolytic factors that are secreted during platelet activation. Therefore, the presence of TAFI in platelets was analyzed. TAFI was identified in platelets in a concentration of about 50 ng/1 x 10(9) platelets and was secreted on platelet activation. Thrombi n-mediated activation of platelet-derived TAFI resembled that of plasma-derived TAFI with respect to stimulation by thrombomodulin and spontaneous loss of activity at 37degreesC. The different glycosylation of platelet-derived TAFI compared with plasma-derived TAFI suggets that platelet-derived TAFI is synthesized in the megakaryocyte. This suggestion was substantiated by the detection of mRNA in the megakaryocytic cell lines DAMI and CHRF, representing the intermediate and late stages of megalkaryocyte development. These results establish the presence of TAFI in platelets and suggest a role for platelet-derived TAFI in the protection of the clot against fibrinolysis. (Blood. 2003;101:4844-4846)

AB - Thrombin activatable fibrinolysis inhibitor (TAFI) is a carboxypeptidase B-like proenzyme that after activation downregulates fibrinolysis. Platelets are known to contain antifibrinolytic factors that are secreted during platelet activation. Therefore, the presence of TAFI in platelets was analyzed. TAFI was identified in platelets in a concentration of about 50 ng/1 x 10(9) platelets and was secreted on platelet activation. Thrombi n-mediated activation of platelet-derived TAFI resembled that of plasma-derived TAFI with respect to stimulation by thrombomodulin and spontaneous loss of activity at 37degreesC. The different glycosylation of platelet-derived TAFI compared with plasma-derived TAFI suggets that platelet-derived TAFI is synthesized in the megakaryocyte. This suggestion was substantiated by the detection of mRNA in the megakaryocytic cell lines DAMI and CHRF, representing the intermediate and late stages of megalkaryocyte development. These results establish the presence of TAFI in platelets and suggest a role for platelet-derived TAFI in the protection of the clot against fibrinolysis. (Blood. 2003;101:4844-4846)

U2 - https://doi.org/10.1182/blood-2002-09-2944

DO - https://doi.org/10.1182/blood-2002-09-2944

M3 - Article

C2 - 12595308

SN - 0006-4971

VL - 101

SP - 4844

EP - 4846

JO - Blood

JF - Blood

IS - 12

ER -